tetano
Editor, Senior Moderator
EMBO Mol Med
. 2020 May 19.
doi: 10.15252/emmm.202012421. Online ahead of print.
The Role of interleukin-6 in Monitoring Severe Case of Coronavirus Disease 2019
Tao Liu[SUP] 1 [/SUP], Jieying Zhang[SUP] 1 [/SUP], Yuhui Yang[SUP] 1 [/SUP], Hong Ma[SUP] 1 [/SUP], Zhenyu Li[SUP] 1 [/SUP], Jiaoyue Zhang[SUP] 2 [/SUP], Ji Cheng[SUP] 3 [/SUP], Xiaoyun Zhang[SUP] 4 [/SUP], Yanxia Zhao[SUP] 1 [/SUP], Zihan Xia[SUP] 1 [/SUP], Liling Zhang[SUP] 1 [/SUP], Gang Wu[SUP] 1 [/SUP], Jianhua Yi[SUP] 5 [/SUP]
Affiliations
Abstract
Progression to severe disease is a difficult problem in treating coronavirus disease 2019 (COVID-19). The purpose of this study is to explore changes in markers of severe disease in COVID-19 patients. 69 severe COVID-19 patients were included. Patients with severe disease showed significant lymphocytopenia. Elevated level of lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and D-dimer was found in most severe cases. Baseline interleukin-6 (IL-6) was found to be associated with COVID-19 severity. Indeed, the significant increase of baseline IL-6 was positively correlated to the maximal body temperature during hospitalization and to the increased baseline of CRP, LDH, ferritin and D-dimer. High baseline IL-6 was also associated with more progressed chest computed tomography (CT) findings. Significant decrease in IL-6 and improved CT assessment was found in patients during recovery, while IL-6 was further increased in exacerbated patients. Collectively, our results suggest that the dynamic change in IL-6 can be used as a marker for disease monitoring in patients with severe COVID-19.
Keywords: biomarker; coronavirus disease 2019: interleukin-6; cytokine storm; disease monitoring.
. 2020 May 19.
doi: 10.15252/emmm.202012421. Online ahead of print.
The Role of interleukin-6 in Monitoring Severe Case of Coronavirus Disease 2019
Tao Liu[SUP] 1 [/SUP], Jieying Zhang[SUP] 1 [/SUP], Yuhui Yang[SUP] 1 [/SUP], Hong Ma[SUP] 1 [/SUP], Zhenyu Li[SUP] 1 [/SUP], Jiaoyue Zhang[SUP] 2 [/SUP], Ji Cheng[SUP] 3 [/SUP], Xiaoyun Zhang[SUP] 4 [/SUP], Yanxia Zhao[SUP] 1 [/SUP], Zihan Xia[SUP] 1 [/SUP], Liling Zhang[SUP] 1 [/SUP], Gang Wu[SUP] 1 [/SUP], Jianhua Yi[SUP] 5 [/SUP]
Affiliations
- PMID: 32428990
- DOI: 10.15252/emmm.202012421
Abstract
Progression to severe disease is a difficult problem in treating coronavirus disease 2019 (COVID-19). The purpose of this study is to explore changes in markers of severe disease in COVID-19 patients. 69 severe COVID-19 patients were included. Patients with severe disease showed significant lymphocytopenia. Elevated level of lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin and D-dimer was found in most severe cases. Baseline interleukin-6 (IL-6) was found to be associated with COVID-19 severity. Indeed, the significant increase of baseline IL-6 was positively correlated to the maximal body temperature during hospitalization and to the increased baseline of CRP, LDH, ferritin and D-dimer. High baseline IL-6 was also associated with more progressed chest computed tomography (CT) findings. Significant decrease in IL-6 and improved CT assessment was found in patients during recovery, while IL-6 was further increased in exacerbated patients. Collectively, our results suggest that the dynamic change in IL-6 can be used as a marker for disease monitoring in patients with severe COVID-19.
Keywords: biomarker; coronavirus disease 2019: interleukin-6; cytokine storm; disease monitoring.